Wyeth

Wei Tong

Subodh S Deshmukh

Semiramis Ayral-Kaloustian

Nan Zhang

Yanzhong Wu

Lalitha Krishnan

Lynn Marie Phelan

Clifford William Coughlin

Adam P Michaud

Thai Nguyen

Abdolsamad Tadayon

Chunhao Zhang

Peter John Larkin

Jean Marie Akin

The present invention provides purified crystalline CCI-779 and processes for preparing the same.

Process for the preparation of purified crystalline CCI-779

This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

6-[(substituted)phenyl]triazolopyrimidines as anticancer agents

This invention relates to crystalline polymorphs of (3S)-N-hydroxy4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide, and preparation and uses thereof.

Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[-(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide

Growing community of inventors

Suffern, NY, United States of America

Wei Tong